UBS Group: Raises Moderna's price target from $50 to $150

Odaily reported that UBS Group has raised its price target for Moderna (MRNA.O) from $50 to $150. Earlier reports indicated that Moderna's personalized mRNA cancer vaccine, developed in collaboration with Merck, achieved significant success in a Phase 3 clinical trial targeting high-risk melanoma, marking the world's first mRNA cancer therapy proven effective in a large-scale Phase 3 trial. Following the announcement, Moderna's stock surged nearly 177% in a single day.